Saudi Arabia
+918770708752

Afanat 40 Pharmaceutical Supplier Specifications for Oncology Procurement

A product name alone cannot establish what will arrive, whether it is authorised for your market, or whether the shipment meets the buyer’s quality requirements. By the end, you will have a practical specification, verification, receiving and supplier-comparison framework for ordering afatinib 40 mg tablets safely and lawfully.

Key takeaways

  • Confirm afatinib 40 mg film-coated tablets and oral administration.
  • Request batch records, certificates of analysis and stability data.
  • Verify import licences, product registration and sale authorisation.
  • Specify temperature limits, shipping records and receiving inspection steps.

What must an Afanat 40 supplier specification sheet contain?

The sheet must identify the medicine as afatinib 40 mg film-coated tablets for oral administration. “Afanat 40” alone is not proof of composition, strength or regulatory identity.

Record these physical details before issuing the purchase order:

  • Exact tablet composition, including excipients or a clear tablet-composition statement
  • Tablets per pack and primary pack type, such as blister or bottle
  • Carton configuration, tamper evidence and desiccant requirement where applicable
  • Labelled storage statement, protection from moisture or light, and shelf life
  • Manufacturer, marketing-authorisation holder, manufacturing site, packing site, country of manufacture and country of registration
  • Product status: original brand, licensed generic or trade-name product
  • Exact label version and pack artwork, not catalogue wording

A 40 mg pack is not an automatic substitute for another presentation. The comparison belongs in the specification.

PresentationWhat to verifyProcurement consequence
40 mgAfatinib strength and approved packSuitable only when 40 mg is prescribed
Reduced strengthAvailable 10 mg dose steps and 20 mg lowest listed doseRequired after clinically directed dose reduction
Other strengthLabel, pack count and regulatory identityDo not substitute without approval

Ask for the product specification, approved package insert, sample carton and photographs of the primary pack. Reconcile the brand, active ingredient, strength, manufacturer, batch number, expiry date and regulatory identity across every document.

Searches for af anat 40 pharmaceutical supplier and af anat 40 supplier can return different listings. Approve the product only when the physical pack and regulatory records agree.

Which clinical and molecular details must procurement verify?

Procurement can approve the clinical match only after a confirmed molecular result and oncology prescriber’s assessment; purchasing staff must not select treatment from a test result alone.

Require the pathology or molecular report to identify:

  • Tested specimen, assay platform, report date and laboratory
  • Quality-control results and exact EGFR alteration wording
  • Whether the finding is an EGFR exon 19 deletion, L858R, uncommon alteration, non-classical alteration or alteration outside the approved indication

Every EGFR result is not equivalent. Do not treat an exon 19 deletion or L858R as interchangeable with an unapproved or weakly established alteration.

The supplier file must contain the destination-market package insert. Use it to verify administration schedule, food timing, dose-adjustment framework, handling instructions and available strengths; do not invent directions or substitute another market’s label. Confirm the insert’s warnings and monitoring requirements for diarrhoea, rash or acneiform dermatitis, stomatitis, paronychia, dry skin, hepatic function and cardiac function.

Check P-glycoprotein inhibitors and inducers against the label’s interaction instructions, including any dose or administration separation.

A certificate of analysis confirms batch quality tests, not mutation eligibility, dosing or interaction management. An afatinib tablet supplier must also distinguish products by clinical scope:

DrugTarget or coverageProcurement comparison
AfatinibIrreversible ErbB-family inhibitor; label-defined EGFR mutationsConfirm indication, strength and dose
Gefitinib or erlotinibEGFR tyrosine-kinase inhibitionDifferent mutation coverage, dose and indications
OsimertinibEGFR-directed therapy with distinct label-defined coverageNot an automatic substitute

Treat dose, target, mutation coverage and indication as separate checks.

Which regulatory documents prove the product can be imported and sold?

A quotation becomes legally usable only after you prove that Afanat 40 can enter and be sold in the destination market. Manufacture or export from India does not establish legal sale in Saudi Arabia or elsewhere.

For Afanat 40 oncology procurement, request these documents:

  • Approved product specification and package insert
  • Batch-specific certificate of analysis (CoA)
  • Certificate of Pharmaceutical Product (CPP) or destination-equivalent document
  • Certificate of origin
  • GMP evidence
  • Manufacturing and packing-site names and addresses
  • Batch-release evidence
  • Stability data
  • Export documents
  • Destination-market registration or import authorisation

Confirm the CoA; do not assume it exists because a supplier claims “WHO-GMP.” The batch record must address identity, assay, related substances, dissolution, dosage-unit uniformity, moisture or water, microbial quality where specified, and compliance with the registered specification. GMP status alone does not prove that this batch passed those tests.

DocumentWhat it establishesWhat it does not establish
CoAThis batch meets its finished-product specificationPermission to sell in the destination
CPP or equivalentRegulatory status in the issuing countryLocal registration
Import authorisationPermission for the named shipment or productClinical suitability
Stability reportShelf life under tested conditionsValidity after unauthorised repacking

Check whether the importer needs a marketing authorisation, prescription-medicine licence, import permit, pharmacovigilance arrangement, or local-language label. Stability data must match the 40 mg strength, container-closure system and storage conditions, including long-term, accelerated and relevant intermediate studies under ICH Q1A(R2). Confirm whether the product is registered, licensed, or merely available for export.

How should you specify transport, delivery and receiving controls?

A sealed carton is not proof of acceptable transport. Require the supplier to state the labelled storage temperature, protection from moisture and light, transport conditions, excursion policy, and temperature-monitoring method before af anat oncology procurement is approved.

1. Put the exact primary pack on the purchase order: Afanat 40 afatinib 40 mg film-coated tablets, blister or bottle type, tablets per pack, cartons per shipper, desiccant requirement if applicable, tamper evidence, and serialisation or aggregation data where the destination market requires it.

State the minimum remaining shelf life at dispatch and reject short-dated stock below that threshold.

2. Record freight method, insurance responsibility, customs responsibility, Incoterm, delivery lead time, and the logger type, placement, calibration status, and result required with each shipment. Define who investigates a temperature or moisture excursion and who authorises release or rejection.

3. On receipt, match the carton against the purchase order, invoice, packing list, certificate of analysis, and shipping records. Capture product name, strength, dosage form, manufacturer, batch number, printed manufacturing date, expiry-date format, quantity, seal condition, storage statement, and temperature-logger result.

4. Reconcile authorised distribution records, printed batch and expiry details, tamper evidence, and serialisation data where required. A changed bottle, blister, or repacking arrangement can invalidate the original stability evidence unless the configuration is authorised and supported by data.

Do not release stock when the seal, batch, expiry, storage statement, or transport record conflicts across documents. Quarantine it pending documented investigation.

How do you compare an Afanat 40 supplier before placing an order?

A stronger Afanat 40 supplier proves product identity before offering a low price. Confirm that the pack is an afatinib 40 mg film-coated tablet, then reconcile its brand, manufacturer, marketing-authorisation holder, manufacturing country, batch number and expiry date with the label and regulatory records.

Send this enquiry to every Afanat 40 supplier:

  • State available stock, exact blister or bottle presentation, tablets per pack, batch and expiry, remaining shelf life, manufacturer, marketing-authorisation holder, manufacturing country, sample label and package insert.
  • Request the batch-specific certificate of analysis, certificate of pharmaceutical product, GMP evidence, registration status, shipping conditions, lead time, minimum order quantity, quotation validity, payment terms, Incoterm, freight method, insurance, customs role, complaint contact, recall process, pharmacovigilance support and replacement terms.

Score the replies against the same criteria:

SupplierWhat to verifyWhy it matters
Manufacturer traceabilitySite, country, batch-release evidencePrevents an untraceable oncology product entering stock
Regulatory statusRegistration or import authorisation in the destinationExport availability does not prove legal sale
Documentation qualityCoA covering identity, assay, dissolution, uniformity and related substancesA WHO-GMP claim alone does not prove batch compliance
Continuity and responseStock history, lead time and complete answersDelays and evasive replies create treatment and compliance risk

An afatinib tablet supplier must not substitute brands, manufacturers or strengths without checking local rules, the purchase order, prescriber or hospital policy and the destination label. A different afatinib strength is not an automatic substitute.

Evaluate NIBA HEALTHCARE by its exact-product identification, verifiable batch documents, export responsibility and compliant-delivery support—not its Riyadh location alone. Record why the supplier and presentation were approved.

Related product

AFANAT 40MG

AFATINIB

AFANAT 40MG

Afanat 40 Tablet is used in the treatment of non-small cell lung cancer.

View product →

Frequently asked questions

  • What must an Afanat 40 supplier specification sheet contain?

    It must identify Afanat 40 as afatinib 40 mg film-coated tablets for oral administration, with the composition, dosage form, pack size, batch details and storage conditions.

  • Which clinical and molecular details must procurement verify?

    Verify the active ingredient, 40 mg strength, tablet formulation, intended oral route, approved indication, molecular identity and supporting quality documents such as assay and dissolution results.

  • Which regulatory documents prove the product can be imported and sold?

    Request the manufacturer’s licence, product registration or marketing authorisation, certificate of pharmaceutical product, certificate of analysis and import documentation required by the destination market.

  • How should you specify transport, delivery and receiving controls?

    Set written temperature, humidity, packaging, delivery-time and excursion-reporting requirements, then inspect seals, batch numbers, expiry dates and shipping records on receipt.

  • How do you compare an Afanat 40 supplier before placing an order?

    Compare regulatory status, batch evidence, remaining shelf life, minimum order quantity, lead time, packaging, complaint handling and the supplier’s ability to document transport conditions.

 2026-10-20T06:32:31

Keywords